Zhigang Lu

6PUBLICATIONS
26CO-AUTHORS
Innate immunityMedical mycologyHaematological tumoursGlycoconjugatesCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 15, 2026
CD300ld on pathologically activated neutrophils promotes tumor immune suppression by binding phosphatidylserine on CD8+ T cells.

|Jan 11, 2024
Targeting PMN-MDSCs via CD300ld receptor for cancer immunotherapy.

Yuwei Li, Chaoxiong Wang, Zhigang Lu

|Sep 06, 2023
CD300ld on neutrophils is required for tumour-driven immune suppression.

Chaoxiong Wang, Xichen Zheng, Jinlan Zhang

|Apr 02, 2022
Author Correction: Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2.

Yunqing Gu, Jun Cao, Xinyu Zhang

|Nov 27, 2021
Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2.

Yunqing Gu, Jun Cao, Xinyu Zhang

|Mar 11, 2021
Oxidative phosphorylation enhances the leukemogenic capacity and resistance to chemotherapy of B cell acute lymphoblastic leukemia.

Chiqi Chen, Xiaoxin Hao, Xiaoyun Lai

Pageof 1

Frequent Collaborators

3 joint publications

Min Luo

3 joint publications

Dong Gao

2 joint publications

Peixuan Zheng

2 joint publications

Yun Zhao